137 related articles for article (PubMed ID: 14644825)
1. The levonorgestrel intrauterine system: a clinical perspective from the UK.
Guillebaud J
Ann N Y Acad Sci; 2003 Nov; 997():185-93. PubMed ID: 14644825
[TBL] [Abstract][Full Text] [Related]
2. Intrauterine contraception--what now and what next?
Guillebaud J
Eur J Contracept Reprod Health Care; 2001 Jan; 6 Suppl 1():11-4. PubMed ID: 11336428
[TBL] [Abstract][Full Text] [Related]
3. Intrauterine contraception - what now and what next?
Guillebaud J
Eur J Contracept Reprod Health Care; 2001; 6 Suppl 1():11-4. PubMed ID: 25104509
[TBL] [Abstract][Full Text] [Related]
4. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
Sturridge F; Guillebaud J
Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
[TBL] [Abstract][Full Text] [Related]
5. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
[TBL] [Abstract][Full Text] [Related]
6. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery.
Critchley HO; Wang H; Jones RL; Kelly RW; Drudy TA; Gebbie AE; Buckley CH; McNeilly AS; Glasier AF
Hum Reprod; 1998 May; 13(5):1218-24. PubMed ID: 9647550
[TBL] [Abstract][Full Text] [Related]
7. Benefit-risk assessment of the levonorgestrel intrauterine system in contraception.
Backman T
Drug Saf; 2004; 27(15):1185-204. PubMed ID: 15588115
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of low-dose levonorgestrel-releasing intrauterine system in Chinese women: a multicenter, single-arm, open labeled interventional trial].
Qian CF; Fan GS; Liao QP; Wu SY; La DD; Di W; Dong BH; Liu HW; Tang LD; Xiong ZA; Zhang HW; Hu YL; Yang NM; Ren ML; Shi H; Deng GP; Huang ZR
Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):409-413. PubMed ID: 29961284
[No Abstract] [Full Text] [Related]
9. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies.
Apter D; Gemzell-Danielsson K; Hauck B; Rosen K; Zurth C
Fertil Steril; 2014 Jun; 101(6):1656-62.e1-4. PubMed ID: 24726226
[TBL] [Abstract][Full Text] [Related]
10. The benefits and risks of using a levonorgestrel-releasing intrauterine system for contraception.
Mansour D
Contraception; 2012 Mar; 85(3):224-34. PubMed ID: 22067761
[TBL] [Abstract][Full Text] [Related]
11. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use.
Gemzell-Danielsson K; Apter D; Dermout S; Faustmann T; Rosen K; Schmelter T; Merz M; Nelson A
Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():22-28. PubMed ID: 27930941
[TBL] [Abstract][Full Text] [Related]
13. A Phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5mg) in postmenarcheal adolescents.
Gemzell-Danielsson K; Buhling KJ; Dermout SM; Lukkari-Lax E; Montegriffo E; Apter D
Contraception; 2016 Jun; 93(6):507-12. PubMed ID: 26872720
[TBL] [Abstract][Full Text] [Related]
14. A single-arm phase III study exploring the efficacy and safety of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5 mg), in an Asia-Pacific population.
Fan G; Kang S; Ren M; Weisberg E; Lukkari-Lax E; Roth K; Shin S
Contraception; 2017 Apr; 95(4):371-377. PubMed ID: 27913229
[TBL] [Abstract][Full Text] [Related]
15. Contraceptive and therapeutic effects of the levonorgestrel intrauterine system: an overview.
Jensen JT
Obstet Gynecol Surv; 2005 Sep; 60(9):604-12. PubMed ID: 16121115
[TBL] [Abstract][Full Text] [Related]
16. Why perimenopausal women should consider to use a levonorgestrel intrauterine system.
Wildemeersch D
Gynecol Endocrinol; 2016 Aug; 32(8):659-661. PubMed ID: 26930021
[TBL] [Abstract][Full Text] [Related]
17. Mirena (Levonorgestrel intrauterine system): a successful novel drug delivery option in contraception.
Rose S; Chaudhari A; Peterson CM
Adv Drug Deliv Rev; 2009 Aug; 61(10):808-12. PubMed ID: 19445984
[TBL] [Abstract][Full Text] [Related]
18. Progestin-releasing intrauterine systems.
Luukkainen T; Pakarinen P; Toivonen J
Semin Reprod Med; 2001 Dec; 19(4):355-63. PubMed ID: 11727177
[TBL] [Abstract][Full Text] [Related]
19. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
Wildemeersch D; Janssens D; Andrade A
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
[TBL] [Abstract][Full Text] [Related]
20. Local levonorgestrel regulation of androgen receptor and 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrium.
Burton KA; Henderson TA; Hillier SG; Mason JI; Habib F; Brenner RM; Critchley HO
Hum Reprod; 2003 Dec; 18(12):2610-7. PubMed ID: 14645180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
